Affinage

MFAP5

Microfibrillar-associated protein 5 · UniProt Q13361

Length
173 aa
Mass
19.6 kDa
Annotated
2026-06-10
56 papers in source corpus 26 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MFAP5 (MAGP-2) is a small cysteine-rich extracellular matrix glycoprotein of elastin-associated microfibrils that bridges structural matrix assembly and cell signaling (PMID:8557636, PMID:9671438). It binds fibrillin-1 and fibrillin-2 through a core domain containing seven conserved cysteines, docking onto a calcium-binding EGF-like region near the fibrillin C-terminus, and this microfibril association requires a dedicated matrix-binding domain that is positively regulated by proprotein convertase cleavage (PMID:12122015, PMID:25153248). Through this localization MFAP5 stimulates elastic fiber assembly independently of tropoelastin levels and independently of its RGD motif (PMID:17099216). Beyond its structural role, MFAP5 is a multifunctional modulator of Notch signaling: it binds the EGF-like repeats of Notch1 and the DSL ligand Jagged1, promoting metalloproteinase-dependent shedding of the Jagged1 ectodomain and furin-dependent release of the Notch1 extracellular domain (PMID:15788413, PMID:16492672). The signaling output is context-dependent—it represses Notch and promotes angiogenic sprouting in endothelial cells while activating Notch in heterologous cells, a cell-type specificity governed by its RGD motif engaging RGD-binding integrins (PMID:18417156, PMID:26808411). MFAP5 also binds active TGFβ1, TGFβ2, and BMP2 (PMID:23963447). In cancer-associated fibroblasts and tumor cells it activates FAK/CREB/TNNC1, NOTCH2/HEY1, and TGF-β/Notch programs to drive proliferation, motility, invasion, and metastasis, and it stabilizes intracellular uPAR by blocking its lysosomal degradation (PMID:25277212, PMID:32293074, PMID:34915136). In genetic loss-of-function studies, Mfap5-/- mice show neutropenia, and combined loss with MAGP1 causes age-dependent aortic dilation, while MFAP5 loss also impairs wound healing with reduced fibroblast migration, collagen deposition, and angiogenesis (PMID:23963447, PMID:41348119). MFAP5 additionally promotes osteogenic differentiation via LRP5/β-catenin signaling (PMID:38348695).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 1996 High

    Established MFAP5 as a discrete microfibril component distinct from its homolog MAGP-1, defining the cysteine-rich core and RGD motif that would later prove functionally central.

    Evidence Peptide sequencing, cDNA cloning, and immunoelectron microscopy of elastin-associated microfibrils

    PMID:8557636

    Open questions at the time
    • Function of the RGD motif not yet defined
    • Binding partners not yet identified
  2. 1998 High

    Mapped the tissue distribution of MFAP5 on fibrillin microfibrils, showing it is more restricted than MAGP-1 and predicting non-redundant roles.

    Evidence Immunoelectron microscopy and Northern blotting across multiple tissues

    PMID:9671438

    Open questions at the time
    • Does not establish the molecular basis of the restricted distribution
    • No functional consequence tested
  3. 2002 High

    Identified the direct fibrillin-1/fibrillin-2 binding interaction and mapped it to the conserved cysteine core, defining how MFAP5 anchors to microfibrils at a site distinct from MAGP-1.

    Evidence Yeast two-hybrid with deletion mapping and reciprocal co-IP in COS-7 cells

    PMID:11796718 PMID:12122015

    Open questions at the time
    • Stoichiometry and affinity not quantified
    • A single amino acid change blocking matrix association left mechanism of matrix targeting incomplete
  4. 2006 High

    Demonstrated that MFAP5 actively stimulates elastic fiber assembly rather than serving as a passive scaffold, and excluded integrin/RGD involvement in this structural function.

    Evidence Doxycycline-regulated overexpression with electron microscopy and RGD mutagenesis

    PMID:17099216

    Open questions at the time
    • Molecular mechanism by which MFAP5 promotes tropoelastin deposition not resolved
    • Single in vitro cell system
  5. 2006 High

    Revealed MFAP5's signaling role by showing it binds Notch1 and Jagged1 EGF-like repeats and triggers ectodomain shedding/release, distinguishing it functionally from MAGP-1.

    Evidence Yeast two-hybrid, co-IP, shedding assays with metalloproteinase inhibitor, and Notch reporter assays with cleavage-requirement dissection

    PMID:15788413 PMID:16492672

    Open questions at the time
    • Whether shedding occurs at physiological MFAP5 levels in vivo unclear
    • Distinction between activation and repression not yet explained
  6. 2016 High

    Resolved the context-dependence of Notch modulation, showing the RGD–integrin axis determines whether MFAP5 represses or activates Notch in a given cell type.

    Evidence Hes1 reporter assays with RGD→RGE mutagenesis, soluble RGD peptides, and β1/β3 integrin blocking antibodies

    PMID:18417156 PMID:26808411

    Open questions at the time
    • Specific integrin heterodimer not pinned to each cell context
    • Mechanistic link between integrin engagement and Notch processing incomplete
  7. 2013 High

    Provided in vivo genetic loss-of-function evidence for MFAP5 in hematopoiesis and vessel integrity and showed it binds active growth factors, establishing a TGF-β/BMP reservoir role.

    Evidence Mfap5-/- and MAGP1;MAGP2 double-knockout mice with blood counts and vascular compliance, plus solid-phase TGF-β/BMP2 binding assays

    PMID:23963447

    Open questions at the time
    • Mechanism linking MFAP5 to neutrophil numbers unknown
    • Whether growth-factor sequestration drives the vascular phenotype untested
  8. 2021 Medium

    Expanded MFAP5 function to an intracellular, signaling-stabilizing role by showing it binds and protects uPAR from lysosomal degradation to drive tumor proliferation.

    Evidence Co-IP, proteomics, lysosomal degradation assay, and xenograft with uPAR knockdown rescue

    PMID:34915136

    Open questions at the time
    • How a secreted ECM protein accesses an intracellular pool not clarified
    • Single lab and cancer context
  9. 2023 Medium

    Consolidated MFAP5 as a cancer-associated fibroblast effector across tumor types, activating multiple signaling axes (FAK/CREB/TNNC1, NOTCH2/HEY1, TGF-β/Notch, RCN2/ERK/STAT1) to remodel stroma and promote progression.

    Evidence siRNA/shRNA knockdown, co-IP for NOTCH2, RNA-seq/ATAC-seq, pathway inhibitor and neutralizing-antibody rescue across multiple cancer models

    PMID:25277212 PMID:31775892 PMID:32293074 PMID:37156839

    Open questions at the time
    • Receptor usage differs across studies without unifying mechanism
    • Direct vs indirect pathway engagement not always distinguished
  10. 2025 High

    Defined MFAP5's role in fibroblast-driven tissue repair and matrix mineralization, linking the gene to wound healing, osteogenesis (LRP5/β-catenin), and dentin formation.

    Evidence Mfap5-/- wound-healing model with single-cell RNA-seq and fibroblast functional assays; co-IP and LRP5 knockdown rescue for osteogenesis

    PMID:38348695 PMID:41348119 PMID:41516268

    Open questions at the time
    • Whether wound-healing and osteogenic effects share a common receptor unresolved
    • ITGA5 interaction not rigorously validated

Open questions

Synthesis pass · forward-looking unresolved questions
  • How MFAP5's distinct structural (microfibril/elastic fiber), growth-factor-reservoir, and receptor-signaling activities are integrated and partitioned across cell types and intracellular versus extracellular pools remains unresolved.
  • No structural model of MFAP5 bound to its receptors
  • Mechanism switching MFAP5 between Notch activation and repression not fully defined
  • No human Mendelian disease link established in the corpus

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0005198 structural molecule activity 3 GO:0048018 receptor ligand activity 3 GO:0008092 cytoskeletal protein binding 1
Localization
GO:0031012 extracellular matrix 4 GO:0005576 extracellular region 3 GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-1643685 Disease 4 R-HSA-1474244 Extracellular matrix organization 3 R-HSA-1266738 Developmental Biology 2
Partners
FBN1FBN2ITGA5JAG1LRP5NOTCH1NOTCH2PLAUR
Complex memberships
fibrillin microfibril

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 MP25 (MAGP-2/MFAP5) was identified as a distinct component of elastin-associated microfibrils by immunofluorescence and immunoelectron microscopy. Its primary structure contains 173 amino acids with significant homology to MAGP-1 confined to a central 60-amino acid cysteine-rich region (7 conserved cysteines), and it contains an RGD motif but lacks proline-, glutamine-, and tyrosine-rich sequences and hydrophobic carboxyl terminus characteristic of MAGP-1, suggesting distinct functions. Peptide sequencing, cDNA cloning, immunofluorescence, immunoelectron microscopy, sequence homology analysis The Journal of biological chemistry High 8557636
1998 MAGP-2 (MFAP5) is specifically associated with fibrillin-containing microfibrils in multiple tissues (nuchal ligament, dermis, adventitia, glomerular mesangium, perimysium) as confirmed by immunoelectron microscopy, but has a more restricted tissue distribution than MAGP-1, being absent from medial layer of fetal thoracic aorta and ocular zonule where MAGP-1 is present. Immunoelectron microscopy, immunolocalization, Northern blotting The journal of histochemistry and cytochemistry High 9671438
2002 MAGP-2 (MFAP5) specifically interacts with fibrillin-1 and fibrillin-2 via a calcium-binding EGF-like repeat-containing region near the C-terminus of the fibrillins. Binding occurs through a core region of MAGP-2 containing 7 conserved cysteine residues. The fibrillin-1 binding site for MAGP-2 is distinct from the MAGP-1 binding site on fibrillin-1. Interaction was confirmed by co-immunoprecipitation from transfected COS-7 cells. Yeast two-hybrid library screen, deletion analysis, co-immunoprecipitation from transfected COS-7 cells The Journal of biological chemistry High 12122015
2002 MAGP-2 (MFAP5) contains a matrix-binding domain similar to the 54-amino acid C-terminal cysteine-rich domain of MAGP-1, but a single amino acid change prevents MAGP-2 from associating with the ECM in the same mammalian cell model used to demonstrate MAGP-1 matrix binding. Deletion constructs expressed in mammalian cells, GFP fusion localization The Journal of biological chemistry Medium 11796718
2005 MAGP-2 (MFAP5) interacts with the Notch ligand Jagged1 via the EGF-like repeats of Jagged1, and promotes shedding of the Jagged1 extracellular domain in a metalloproteinase-dependent manner (blocked by hydroxamate inhibitor BB3103). MAGP-2 also interacts with Jagged2 and Delta1 but does not facilitate their shedding. MAGP-1 interacts with DSL ligands but cannot facilitate Jagged1 shedding. Yeast two-hybrid, co-immunoprecipitation, conditioned media analysis, metalloproteinase inhibitor treatment The Journal of biological chemistry High 15788413
2006 MAGP-2 (MFAP5) directly interacts with the EGF-like repeats of Notch1, and co-expression of MAGP-2 with Notch1 leads to cell surface release of the Notch1 extracellular domain and subsequent activation of Notch signaling. The C-terminal domain of MAGP-2 is required for Notch1 binding and activation. Notch1 extracellular domain release by MAGP-2 requires furin-like cleavage for Notch1 heterodimer formation but does not require subsequent ADAM metalloprotease cleavage. Co-expression studies, Notch signaling reporter assays, domain deletion analysis, cell surface release assays The Journal of biological chemistry High 16492672
2006 Microfibril-associated MAGP-2 (MFAP5) stimulates elastic fiber assembly independently of extracellular tropoelastin levels. Electron microscopy showed MAGP-2 specifically associates with microfibrils and elastin globules co-localize with MAGP-2-associated microfibrils. The RGD motif of MAGP-2 is not required for this stimulation of elastic fiber assembly, ruling out integrin receptor binding as the mechanism. MAGP-2 overexpression did not change levels of fibrillin-1, MAGP-1, fibulin-2, fibulin-5, or emilin-1. Doxycycline-regulated conditional overexpression system, immunofluorescence, electron microscopy, mutation analysis of RGD motif The Journal of biological chemistry High 17099216
2008 MAGP-2 (MFAP5) promotes angiogenic cell sprouting by antagonizing Notch signaling in endothelial cells specifically: MAGP-2 decreased basal and Jagged1-induced Hes-1 promoter activity and blocked Jagged1-stimulated Notch1 receptor processing in endothelial cells, but increased Hes-1 promoter activity in heterologous cell types. Constitutive activation of Notch blocked MAGP-2-promoted angiogenic sprouting. Hes-1 promoter luciferase reporter assay, Notch1 receptor processing assay in transfected 293T cells, angiogenic sprouting assay, constitutively active Notch rescue experiment Microvascular research High 18417156
2013 MAGP2 (MFAP5) binds active TGFβ1, TGFβ2, and BMP2 in solid phase binding assays. Loss of MAGP2 in Mfap5-/- mice causes neutropenia (contrasting with monocytopenia in MAGP1-deficient mice), and MAGP1;MAGP2 double knockout mice show age-dependent aortic dilation, indicating shared primary functions of MAGPs in large vessel integrity. Solid phase binding assay, targeted gene inactivation (Mfap5-/- mice), blood cell counts, vascular compliance measurements The Journal of biological chemistry High 23963447
2014 MFAP5 (MAGP-2) binding to microfibrils requires its conserved Matrix Binding Domain, and this matrix association is positively regulated by proprotein convertase (PC) cleavage of MAGP2. Mutation of the MAGP2 PC consensus site reduced matrix-associated MAGP2. The C-terminal 20-amino acid domain defined by the PC cleavage site also positively modulates matrix localization in a manner requiring the amino-terminal half of the protein. Immunofluorescence co-localization with fibrillin-2 microfibrils, PC consensus site mutagenesis, deletion analysis, overexpression in T3 ovarian cells Matrix biology Medium 25153248
2014 MFAP5 (MAGP-2) activates FAK/CREB/TNNC1 signaling to promote ovarian cancer cell motility and invasion. Targeting stromal MFAP5 with siRNA in chitosan nanoparticles significantly decreased ovarian tumor growth and metastasis in vivo. siRNA knockdown, signaling pathway analysis, in vivo mouse tumor model with nanoparticle-delivered siRNA Nature communications Medium 25277212
2016 MAGP2 (MFAP5) controls Notch signaling in a cell-type-dependent manner through its RGD motif interacting with RGD-binding integrins: in endothelial cells, wild-type MAGP2 suppresses Hes1 promoter activity while a RGD→RGE MAGP2 mutant increases Notch signaling. Inhibition of RGD-binding integrins with soluble RGD peptides or β1/β3 integrin blocking antibodies increased active N1ICD accumulation and Notch responsive promoter activity independently of changes in Notch1, Jag1, or Dll4 expression. Hes1 promoter luciferase reporter assay, RGD→RGE point mutagenesis, soluble RGD peptide inhibition, integrin blocking antibodies, N1ICD accumulation assay Experimental cell research High 26808411
2018 MFAP5 promotes breast cancer cell proliferation and migration by increasing expression of MMP2 and MMP9 and activating the ERK signaling pathway (p-FAK, p-ERK1/2, p-cJun). Inhibition of MFAP5 suppressed these downstream signaling molecules. Overexpression and knockdown, Western blot for signaling proteins, cell proliferation and migration assays Biochemical and biophysical research communications Low 29526753
2018 MFAP5 is enriched in cancer-associated fibroblast (CAF) secretomes relative to adjacent tissue fibroblasts, and recombinant MFAP5 activates OTSCC cell growth and migration via activation of MAPK and AKT pathways. Shotgun proteomics of CAF secretomes, in vitro recombinant protein treatment, MAPK/AKT pathway analysis Journal of proteome research Medium 29681158
2019 MFAP5 knockdown in cervical cancer cells induces apoptosis through ROS production, activates JNK, reduces Bcl-xl and Bcl-2, and increases Bax and cleaved Caspase-3. MFAP5 knockdown also induces G2/M cell cycle arrest with reduced Cyclin B1, Cyclin D1, and CDK4, and increased p21 and p53. The growth inhibitory effect of MFAP5 knockdown is dependent on ROS production. siRNA knockdown, ROS measurement, cell cycle analysis, Western blot for apoptosis/cell cycle markers, in vivo xenograft, ROS rescue experiment Biochemical and biophysical research communications Medium 30454902
2019 CAF-derived MFAP5 promotes bladder cancer proliferation and metastasis via direct interaction with the NOTCH2 receptor, stimulating N2ICD release and activating NOTCH2/HEY1 signaling. QKI directly downregulates MFAP5 in CAFs as shown by luciferase reporter and EMSA. MFAP5-mediated PI3K-AKT signaling activates the DLL4/NOTCH2 pathway axis. Downregulation of NOTCH2 by shRNA or NRR2Mab antibody reverses the adverse effects of MFAP5 stimulation. Co-IP (MFAP5 direct interaction with NOTCH2), luciferase reporter assay, EMSA, RNA-sequencing, shRNA knockdown, neutralizing antibody NRR2Mab, in vitro and in vivo rescue experiments FASEB journal High 32293074
2019 CAF-secreted MFAP5 drives invasion and migration of MCF7 breast cancer cells via activation of Notch1 signaling, upregulating NICD1 and Slug. Notch1 knockdown in MCF7 cells decreased the ability of MFAP5 to promote invasion and migration. Proteomic analysis of CAF secretomes, Transwell and wound healing assays, Notch1 knockdown, Western blot for NICD1 and Slug Clinical & translational oncology Medium 31190277
2019 MFAP5 promotes basal-like breast cancer metastasis via the TGF-β/Notch pathway: TGF-β or Notch inhibitors significantly reversed tumorigenicity and metastasis of MFAP5-induced BLBC cells in vitro and in vivo. Overexpression and knockdown, in vitro proliferation/migration/invasion assays, in vivo tail vein metastasis model, TGF-β and Notch pathway inhibitor rescue Cell & bioscience Medium 30899449
2019 MFAP5 facilitates intrahepatic cholangiocarcinoma (ICC) cell growth and G1-to-S phase transition through regulation of the Notch1 signaling pathway, as revealed by RNA-seq and ATAC-seq of MFAP5-suppressed ICC cells. The Notch signaling inhibitor FLI-06 completely abolished MFAP5-dependent transcriptional programs. RNA-seq, ATAC-seq, shRNA knockdown, Notch inhibitor (FLI-06) treatment, CCK8 and colony formation assays, cell cycle analysis, xenograft model Journal of experimental & clinical cancer research Medium 31775892
2021 Intracellular MAGP2 (MFAP5) directly interacts with urokinase-type plasminogen activator receptor (uPAR) and inhibits lysosomal-mediated degradation of uPAR, thereby increasing uPAR stability. Elevated MAGP2 promotes tumor cell proliferation through uPAR-mediated p38-NF-κB signaling axis activation, enhanced DNA damage repair, and reduction of S-phase cell stagnation. Co-immunoprecipitation (direct interaction with uPAR), proteomics analysis, lysosomal degradation assay, p38-NF-κB pathway analysis, xenograft model with uPAR knockdown rescue Cellular signalling Medium 34915136
2023 MFAP5 deficiency in CAFs downregulates HAS2 and CXCL10 via MFAP5/RCN2/ERK/STAT1 axis in pancreatic cancer, leading to reduced angiogenesis, hyaluronic acid and collagen deposition, increased cytotoxic T cell infiltration, and tumor cell apoptosis. In vivo blockade of CXCL10 with AMG487 partially reverses the pro-tumor effect of MFAP5 overexpression in CAFs. MFAP5 knockdown in CAFs, Western blot for RCN2/ERK/STAT1 pathway, CXCL10/HAS2 measurement, in vivo tumor models, AMG487 CXCL10 inhibitor rescue Oncogene Medium 37156839
2024 MAGP2 (MFAP5) promotes osteogenic differentiation and fracture healing through interaction with LRP5 and activation of β-catenin signaling. MAGP2 upregulates LRP5 expression, and LRP5 knockdown partially reverses MAGP2-promoted osteogenic differentiation and β-catenin activation. β-catenin/TCF4 increases MAGP2 expression by binding to the MAGP2 promoter, creating a feedback loop. Co-IP (MAGP2-LRP5 interaction), LRP5 knockdown rescue, ALP activity assay, mineralization assay, in vivo fracture mouse model, mRNA sequencing Journal of cellular physiology Medium 38348695
2025 MFAP5 loss in Mfap5-/- mice impairs wound closure, reduces angiogenesis, enhances neutrophil and macrophage influx, and reduces collagen deposition in normal skin. Mfap5-/- fibroblasts exhibit reduced migration, contractility, proliferation, and ECM deposition in vitro, identifying a direct role for MFAP5 in fibroblast behavior relevant to wound healing. Mfap5-/- mouse wound healing model, single-cell RNA sequencing, in vitro fibroblast isolation and functional assays (migration, contractility, proliferation, ECM deposition), mRNA sequencing FASEB journal High 41348119
2025 MFAP5 engages integrin alpha-5 (ITGA5) to activate ERK/MAPK signaling in odontoblast-lineage cells, promoting odontoblast differentiation and dentin deposition (matrix mineralization). Single-cell RNA sequencing, functional in vitro differentiation/mineralization assays, MFAP5-ITGA5 interaction and ERK/MAPK signaling pathway analysis International journal of molecular sciences Low 41516268
2025 MFAP5 promotes stemness features of NSCLC cells by inducing degradation of FBW7 (a tumor suppressor), which stabilizes Sox9 (a cancer stem cell protein). MFAP5 knockdown increased FBW7 levels and accelerated Sox9 degradation (CHX chase assay). Sox9 overexpression rescued growth/stemness inhibition caused by MFAP5 knockdown. MFAP5 overexpression/knockdown, Western blot for FBW7 and Sox9, CHX degradation assay, Sox9 overexpression rescue, clone formation and sphere culture assays Current pharmaceutical biotechnology Low 38415489
2019 Anti-MFAP5 antibody clone 130A downregulates MFAP5-induced collagen production in CAFs, suppresses intratumoral microvessel leakiness, and enhances paclitaxel bioavailability in ovarian and pancreatic cancer mouse models. Epitope mapping identified a common epitope shared between human and murine MFAP5. Hybridoma antibody development, Octet RED384 binding kinetics, epitope mapping, in vitro collagen production assay, in vivo tumor-bearing mouse models Clinical cancer research Medium 31332047

Source papers

Stage 0 corpus · 56 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1996 Further characterization of proteins associated with elastic fiber microfibrils including the molecular cloning of MAGP-2 (MP25). The Journal of biological chemistry 130 8557636
2014 Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature communications 113 25277212
2006 Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation. The Journal of biological chemistry 106 16492672
2014 MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. American journal of human genetics 96 25434006
1998 Microfibril-associated glycoprotein-2 (MAGP-2) is specifically associated with fibrillin-containing microfibrils but exhibits more restricted patterns of tissue localization and developmental expression than its structural relative MAGP-1. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 80 9671438
2018 Proteomic Analysis of Cancer-Associated Fibroblasts Reveals a Paracrine Role for MFAP5 in Human Oral Tongue Squamous Cell Carcinoma. Journal of proteome research 77 29681158
2008 Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvascular research 67 18417156
2002 Microfibril-associated glycoprotein-2 interacts with fibrillin-1 and fibrillin-2 suggesting a role for MAGP-2 in elastic fiber assembly. The Journal of biological chemistry 63 12122015
2019 Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 60 31332047
2013 Microfibril-associated glycoprotein 2 (MAGP2) loss of function has pleiotropic effects in vivo. The Journal of biological chemistry 59 23963447
2006 Microfibril-associated MAGP-2 stimulates elastic fiber assembly. The Journal of biological chemistry 53 17099216
2018 Microfibril-associated glycoproteins MAGP-1 and MAGP-2 in disease. Matrix biology : journal of the International Society for Matrix Biology 50 29524629
2005 The extracellular matrix protein MAGP-2 interacts with Jagged1 and induces its shedding from the cell surface. The Journal of biological chemistry 48 15788413
2020 CAFs-derived MFAP5 promotes bladder cancer malignant behavior through NOTCH2/HEY1 signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 46 32293074
2015 MFAP5 is related to obesity-associated adipose tissue and extracellular matrix remodeling and inflammation. Obesity (Silver Spring, Md.) 40 26054006
2023 Interactions between MFAP5 + fibroblasts and tumor-infiltrating myeloid cells shape the malignant microenvironment of colorectal cancer. Journal of translational medicine 39 37344903
2002 Identification of a matrix-binding domain in MAGP1 and MAGP2 and intracellular localization of alternative splice forms. The Journal of biological chemistry 39 11796718
2018 MFAP5 promotes tumor progression and bone metastasis by regulating ERK/MMP signaling pathways in breast cancer. Biochemical and biophysical research communications 37 29526753
2019 MFAP5 promotes basal-like breast cancer progression by activating the EMT program. Cell & bioscience 35 30899449
2018 MFAP5 suppression inhibits migration/invasion, regulates cell cycle and induces apoptosis via promoting ROS production in cervical cancer. Biochemical and biophysical research communications 35 30454902
2014 Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Molecular therapy : the journal of the American Society of Gene Therapy 35 24496384
2023 Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Oncogene 33 37156839
2019 MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway. Journal of experimental & clinical cancer research : CR 32 31775892
2016 MAGP2 controls Notch via interactions with RGD binding integrins: Identification of a novel ECM-integrin-Notch signaling axis. Experimental cell research 31 26808411
2019 Stromal fibroblast-derived MFAP5 promotes the invasion and migration of breast cancer cells via Notch1/slug signaling. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25 31190277
2020 Hypoxia-induced MFAP5 Promotes Tumor Migration and Invasion via AKT Pathway in Head and Neck Squamous Cell Carcinoma. Journal of Cancer 16 32047565
2019 MAGP2, a Component of Extracellular Matrix, Is Upregulated in Colorectal Cancer and Negatively Modulated by miR-200b-3p. Technology in cancer research & treatment 14 31426719
2023 Cancer-associated fibroblasts in the invasive tumour front promote the metastasis of oral squamous cell carcinoma through MFAP5 upregulation. Gene 13 37217152
2019 Loss of microfibril-associated protein 5 (MFAP5) expression in colon cancer stroma. Virchows Archiv : an international journal of pathology 13 31422503
2022 High glucose stimulating ECM remodeling and an inflammatory phenotype in the IPFP via upregulation of MFAP5 expression. Biochemical and biophysical research communications 11 35240498
1998 The exon structure of the human MAGP-2 gene. Similarity with the MAGP-1 gene is confined to two exons encoding a cysteine-rich region. The Journal of biological chemistry 11 9792630
2022 Levofloxacin exerts broad-spectrum anticancer activity via regulation of THBS1, LAPTM5, SRD5A3, MFAP5 and P4HA1. Anti-cancer drugs 10 34419964
2000 Organization of the mouse microfibril-associated glycoprotein-2 (MAGP-2) gene. Mammalian genome : official journal of the International Mammalian Genome Society 9 10723723
2021 MAGP2 induces tumor progression by enhancing uPAR-mediated cell proliferation. Cellular signalling 8 34915136
2014 Binding of MAGP2 to microfibrils is regulated by proprotein convertase cleavage. Matrix biology : journal of the International Society for Matrix Biology 8 25153248
2024 Identification of cancer-associated fibrolast subtypes and distinctive role of MFAP5 in CT-detected extramural venous invasion in gastric cancer. Translational oncology 7 39531783
2024 Upregulation of MFAP5 Enhances COL1A1 Expression, Promoting Epithelial-Mesenchymal Transition in Gastric Cancer Cells. Discovery medicine 6 39463228
2024 High-resolution subtyping of fibroblasts in gastric cancer reveals diversity among fibroblast subsets and an association between the MFAP5-fibroblast subset and immunotherapy. Frontiers in immunology 5 39524442
2020 Reduced MFAP5 expression in stroma of gallbladder adenocarcinoma and its potential diagnostic utility. Virchows Archiv : an international journal of pathology 5 32895766
2019 Immunohistochemical Expression of Microfibrillar-associated Protein 5 (MFAP5) in Invasive Breast Carcinoma of No Special Type. Applied immunohistochemistry & molecular morphology : AIMM 5 30320661
2025 Overexpression of MFAP5 inhibits the progression of papillary thyroid cancer and aerobic glycolysis by regulating the EFEMP2/Wnt/β-catenin pathway. Pathology, research and practice 3 40020327
2026 Biodegradable Carbonate Nanogels Loaded with Anti MFAP-5 siRNA for Anti-stromal Therapy of Hepatocellular Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2 41677363
2025 MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis. Current pharmaceutical biotechnology 2 38415489
2024 MAGP2 promotes osteogenic differentiation during fracture healing through its crosstalk with the β-catenin pathway. Journal of cellular physiology 2 38348695
2025 Loss of MFAP5 and Its Effect on Skin Homeostasis and Wound Healing. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1 41348119
2026 Combination of serum TBL1XR1, MFAP5, and PSA as diagnostic biomarkers for prostate cancer. Clinics (Sao Paulo, Brazil) 0 41666500
2026 Deciphering MFAP5+ Fibroblasts in Pancreatic Cancer Progression via Multi-Regional Single-Cell RNA Sequencing With Experimental Validation. Molecular carcinogenesis 0 41995689
2025 Chronic Exposure of Renal Progenitor Cells (HRTPT) to As (III) Implicates Microfibril Associated Protein 5 (MFAP5) in the Activation of Carcinoembryonic Antigen Related Cell Adhesion Molecules (CEACAM 5 and 6). Current issues in molecular biology 0 40699854
2025 Significance of MFAP5, IMP3 and Desmin Expression as Diagnostic Biomarkers for Colorectal Cancers in Biopsy Specimens. International journal of surgical pathology 0 41051977
2025 MFAP5 as a promising biomarker for connective tissue disease-associated interstitial lung disease. Frontiers in immunology 0 41112301
2025 Integrated bulk and single-cell RNA profiling implicates MFAP5+ CAFs in potential role in peritoneal metastasis of gastric cancer. Biochemical and biophysical research communications 0 41205579
2025 [The expression of MFAP5 in ovarian cancer and its effect on cancer cell proliferation, metastasis and drug resistance]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 0 41443738
2025 MFAP5 Activates ITGA5 to Drive Tooth Germ Mineralization Through the MAPK/ERK Pathway: Insights from Single-Cell Transcriptomics. International journal of molecular sciences 0 41516268
2024 Loci cg06256735 and cg15815843 in the MFAP5 gene regulatory regions are hypomethylated in varicose veins apparently due to active demethylation. Bioscience reports 0 38743016
2024 MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro. Open life sciences 0 39759103
2023 MFAP5 variant-induced multiple giant thoracic aortic aneurysm. Cardiology in the young 0 38031457

Missed literature

Know a paper Affinage missed for MFAP5? Flag it for the maintainers and the community.

No submissions yet.